Business Model Innovation Opportunities for the Biopharmaceutical Industry: A Systematic Review
PDF

Supplementary Files

Cover Letter

Keywords

Biotechnology
Business Model
Innovation
Management
Pharmaceutical

Abstract

Research on business model innovation for the biopharmaceutical industry continues to be an area of high global interest due to the combination of industry innovation challenges and global macroeconomic pressures.  Through the use of a systematic literature review the purpose of this research is to explore the universe of academic literature published from 1976 to 2013 that has addressed business model relevant factors and dynamics in the biopharmaceutical industry and inductively mine this literature for insights into the opportunities for business model innovation.  After identifying and reviewing 305 relevant publications, 12 categories were developed and key dynamics discussed.  The author finds that opportunities for business model innovation lie in five key areas, External Orientation, Learning Capabilities, Cluster Participation, Qualified Business Management Team and Organization Controls.  This research provides not only insight into opportunities for business model innovation specific to this industry but also can be used independently as a valuable reference tool for similar research.

https://doi.org/10.5912/jcb735
PDF

References

Marks LV. Collaboration – a competitor’s tool: The story of Centocor, an entrepreneurial biotechnology company. Bus Hist [Internet]. 2009 Jul [cited 2014 Feb 22];51(4):529–46. Available from: http://www.tandfonline.com/doi/abs/10.1080/0007679090299851

Williams A. Corporate development in biotechnology in 2005. J Commer Biotechnol [Internet]. 2005 Apr 1;11(3):239–48. Available from: http://commercialbiotechnology.com/article/view/123

Pisano GP. Science Business: The Promise, the Reality, and the Future of Biotech. [Internet]. Harvard Business School Press. Boston; 2006. 81-82 p. Available from: http://search.ebscohost.com/login.aspx?direct=true&db=buh&AN=22138563&site=ehost-livenhttp://hbr.org/product/a/an/8401-HBK-ENG

Glick JL. Biotechnology business models work : Evidence from the pharmaceutical marketplace. J Commer Biotechnol. 2008;14(2):106–18.

Powell W, Koput K, Smith-Doerr L. Interorganizational Collaboration and the Locus of Innovation: Networks of Learning in Biotechnology. Adm Sci Q [Internet]. 1996 [cited 2014 Aug 23];41:116–45. Available from: http://www.jstor.org/stable/2393988

Rothaermel FT. Complementary assets, strategic alliances, and the incumbent’s advantage: an empirical study of industry and firm effects in the biopharmaceutical industry. Res Policy [Internet]. 2001;30(8):1235–51. Available from: http://www.sciencedirect.com/science/article/pii/S0048733300001426nhttp://www.sciencedirect.com/science/article/pii/S0048733300001426/pdfft?md5=76477ac72306e45ff464933531b43f33&pid=1-s2.0-S0048733300001426-main.pdf

Serono. Serono and Pfizer to Co-Promote Multiple Sclerosis Treatment Rebif(R) in the United States [Internet]. PR Newswire. 2002 [cited 2015 Dec 16]. Available from: http://www.prnewswire.com/news-releases/serono-and-pfizer-to-co-promote-multiple-sclerosis-treatment-rebifr-in-the-united-states-76134692.html

BPI. Revenue of the worldwide pharmaceutical market from 2001 to 2014 [Internet]. In Statista - The Statistics Portal. [cited 2015 Dec 10]. Available from: http://www.statista.com/statistics/263102/pharmaceutical-market-worldwide-revenue-since-2001/

FAZ. Total biopharmaceutical revenue worldwide from 2006 to 2011 (in billion U.S. dollars). [Internet]. In Statista - The Statistics Portal. [cited 2015 Dec 10]. Available from: http://www.statista.com/statistics/282628/global-biopharmaceutical-revenue/.

Moore G. Cramming More Components onto Integrated Circuits. Electronics Magazine. 1965;38(8):114–7.

Scannell J, Anderson T, Redenius J, Clive LB. Global Pharma: Pharma R&D Prodictivity Follows Moore’s Law Backwards. Dows Anyone Know Why? Bernstein Black Book - The Long View: Pan-European Perspectives (2011 Edition). 2011.

Thomson Reuters n. d. 2011 CMR International Pharmaceutical R&D Factbook. London; 2011.

EFPIA. Percentage of spending on research and development of total revenue from 2010 to 2014, by industrial sector [Internet]. In Statista - The Statistics Portal. [cited 2015 Dec 11]. Available from: http://www.statista.com/statistics/270324/expenditure-on-research-and-development-by-industry-sectors/.

DiMasi JA, Grabowski HG. The Cost of Biopharmaceutical R&D: Is Biotech Different? Manag Decis Econ. 2007;28:469–79.

Colby SL, Ortman JM. The Baby Boom Cohort in the United States : 2012 to 2060. Current Population Reports. Washington, DC; 2014.

US Census Bureau. US Census Data: Persons 65 years and over, percent, 2014 [Internet]. Quick Facts. 2014 [cited 2015 Dec 17]. Available from: http://quickfacts.census.gov/qfd/states/00000.html

Centers for Medicare and Medicaid Services. NHE Fact Sheet [Internet]. National Health Expenditure Data. 2014 [cited 2015 Dec 17]. Available from: https://www.cms.gov/research-statistics-data-and-systems/statistics-trends-and-reports/nationalhealthexpenddata/nhe-fact-sheet.html

Teece DJ. Business Models, Business Strategy and Innovation. Long Range Plann [Internet]. 2010;43(2--3):172–94. Available from: http://dx.doi.org/10.1016/j.lrp.2009.07.003

Osterwalder A, Pigneur Y. Clarifying Business Models : Origins , Present , and Future of the Concept Clarifying Business Models : Origins , Present , and Future of the Concept. Commun AIS. 2005;15(May).

Bellman R, Clark CE, Malcolm DG, Craft CJ, Ricciardi FM. On the Construction of a Multi-Stage, Multi-Person Business Game. Operations Research. 1957. p. 469–503.

Jones GM. Educators, Electrons, And Business Models: A Problem In Synthesis. Account Rev. 1960;35(4):619–26.

Zott C, Amit R, Massa L. The business model: Recent developments and future research. J Manage [Internet]. 2011;37(4):1019–42. Available from: http://jom.sagepub.com.ezproxy.liberty.edu:2048/content/37/4/1019

Galambos L, Sturchio JL. Pharmaceutical Firms and the Transition to Biotechnology: A Study in Strategic Innovation. Bus Hist Rev. 1998;72(02):250–78.

Thomson Reuters. Web of Science [Internet]. 2015 [cited 2015 Oct 13]. Available from: http://wokinfo.com/

Ovans A. What is a business model? [Internet]. Harvard Business Review. 2015. p. 1–8. Available from: https://hbr.org/2015/01/what-is-a-business-model

Al-debei MM, El-Haddadeh R, Avison D. Defining the Business Model in the New World of Digital Business. Proc Am Conf Inf Syst [Internet]. 2008;(2000):1–11. Available from: http://bura.brunel.ac.uk/bitstream/2438/2887/1/AMCIS2008.pdf

EBSCO Information Services. EBSCO Business Source Complete [Internet]. 2015. Available from: https://www.ebscohost.com/academic/business-source-complete

Asher AD, Duke LM, Wilson S. Paths of Discovery: Comparing the Search Effectiveness of EBSCO Discovery Service, Summon, Google Scholar, and Conventional Library Resources. Coll Res Libr [Internet]. 2012;74(5):464–88. Available from: http://crl.acrl.org/content/74/5/464

Zott C, Amit R, Massa L. The business model: Theoretical roots, recent developments, and future research. IESE Research Papers. 2010.

Huff A. Designing Research for Publication. London: Sage; 2009.

Blumenthal D, Gluck M, Louis K, Stoto MA, Wise D. University-Industry Research Relationships in Biotechnology: Implications for the University. Science (80- ). 1986;232(4756):1361–6.

Blumenthal D, Gluck M, Louis KS, Wise D. Industrial support of university research in biotechnology. Science [Internet]. 1986;231(4735):242–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3941897

Roberts EB, Hauptman O. The process of technology transfer to the new biomedical and pharmaceutical firm. Res Policy [Internet]. 1986;15(3):107–19. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-0009331919&partnerID=tZOtx3y1

Teece DJ. Profiting from technological innovation: Implications for integration, collaboration, licencing and public policy. Res Policy. 1986;15(6):285–305.

Persidis A, De Rubertis F. Spin-offs vs Start-ups as business models in biotechnology. Nat Biotechnol. 2000;18(5):570–1.

Papadopoulos S. Business models in biotech. Nat Biotechnol. 2000;18 Suppl:IT3–T4.

Casper S. Institutional Adaptiveness, Technology Policy, and the Diffusion of New Business Models: The Case of German Biotechnology.pdf. Organ Stud. 2000;21(5).

Achilladelis B, Antonakis N. The dynamics of technological innovation: The case of the pharmaceutical industry. Res Policy. 2001;30(4):535–88.

Coriat B, Orsi F, Weinstein O. Does Biotech Reflect a New Science-based Innovation Regime? Ind Innov. 2003;10(3):231–53.

Hopkins MM, Martin P a., Nightingale P, Kraft A, Mahdi S. The myth of the biotech revolution: An assessment of technological, clinical and organisational change. Res Policy. 2007;36(4):566–89.

Orsenigo L, Pammolli F, Riccaboni M. Technological change and network dynamics: Lessons from the pharmaceutical industry. Res Policy. 2001;30(3):485–508.

Bagchi-Sen S. Strategic Considerations for Innovation and Commercialization in the US Biotechnology Sector. Eur Plan Stud [Internet]. 2007 Jul;15(6):753–66. Available from: http://www.tandfonline.com/doi/abs/10.1080/09654310701214226

Niosi J. Complexity and path dependence in biotechnology innovation systems. Ind Corp Chang [Internet]. 2011 Dec 1 [cited 2014 Jul 12];20(6):1795–826. Available from: http://icc.oxfordjournals.org/cgi/doi/10.1093/icc/dtr065

Lange K. Institutional embeddedness and the strategic leeway of actors: The case of the German therapeutical biotech industry. Socio-Economic Rev. 2009;7(2):181–207.

Owen-Smith J, Riccaboni M, Pammolli F, Powell WW. A Comparison of U . S . and European University-Industry Relations in the Life Sciences. Manage Sci. 2002;48(1):24–43.

Gittelman M. National institutions, public-private knowledge flows, and innovation performance: A comparative study of the biotechnology industry in the US and France. Res Policy. 2006;35:1052–68.

Glick J. Biotechnology business models work: Evidence from the pharmaceutical marketplace. J Commer Biotechnol [Internet]. 2008 [cited 2014 Jan 26];14(2):106–18. Available from: http://www.palgrave-journals.com/jcb/journal/v14/n2/abs/3050085a.html

Grabowski H, Vernon J, DiMasi JA. Returns on research and development for 1990s new drug introductions. Pharmacoeconomics. 2002;20 Suppl 3:11–29.

Lazonick W, Tulum Ö. US biopharmaceutical finance and the sustainability of the biotech business model. Res Policy [Internet]. 2011 Nov [cited 2014 Mar 21];40(9):1170–87. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0048733311001028

Jensen R, Thursby MC. Proofs and Prototypes for Sale: The Licensing of University Inventions. Am Econ Rev [Internet]. 2001;91(1):240–59. Available from: http://ideas.repec.org/p/nbr/nberwo/6698.html

Zucker LG, Darby MR, Brewer MB, American T, Review E, Mar N. Intellectual Human Capital and the Birth of US Biotechnology Enterprises. Am Econ Rev. 1998;88(1):290–306.

Prevezer M. Ingredients in the early development of the US biotechnology industry. Small Bus Econ [Internet]. 2001 [cited 2014 Aug 4];17:17–29. Available from: http://link.springer.com/article/10.1023/A:1011174421603

DiMasi JA. New drug development in the United States from 1963 to 1999. Clin Pharmacol Ther. 2001;69(5):286–96.

Dalpé R. Interaction between public research organizations and industry in biotechnology. Manag Decis Econ [Internet]. 2003 [cited 2014 Aug 18];24:171–85. Available from: http://onlinelibrary.wiley.com/doi/10.1002/mde.1082/abstract

Quere M. KNOWLEDGE DYNAMICS: BIOTECHNOLOGY’S INCURSION INTO THE PHARMACEUTICAL INDUSTRY. Ind Innov [Internet]. 2003;10(3):255. Available from: http://proquest.umi.com/pqdweb?did=503976771&Fmt=7&clientId=18133&RQT=309&VName=PQD

Nightingale P, Martin P. The myth of the biotech revolution. Trends Biotechnol. 2004;22(11):564–9.

Gottinger H-W, Umali CL. The evolution of the pharmaceutical-biotechnology industry. Bus Hist. 2008;50(5):583–601.

Furman JL, MacGarvie M. Academic collaboration and organizational innovation: The development of research capabilities in the US pharmaceutical industry, 1927-1946. Ind Corp Chang. 2009;18(5):929–61.

Tucker J, Yakatan S, Yakatan S. Biogenerics 2007: How far have we come? J Commer Biotechnol [Internet]. 2008 Jan [cited 2014 Jan 26];14(1):56–64. Available from: http://commercialbiotechnology.com/article/view/228

Malerba F, Orsenigo L. Innovation and market structure in the dynamics of the pharmaceutical industry and biotechnology: towards a historyâ€friendly model. Ind Corp Chang [Internet]. 2002 [cited 2014 Aug 4];11(4):667–703. Available from: http://icc.oxfordjournals.org/content/11/4/667.short

Cooke P. Global Bioregional Networks: A New Economic Geography of Bioscientific Knowledge. Eur Plan Stud. 2006;14(9):1265–85.

Ahn MJ, Meeks M. Building a conducive environment for life science-based entrepreneurship and industry clusters. J Commer Biotechnol. 2008;14(1):20–30.

Papaioannou T. Public–Private Collaboration for New Life Sciences Innovation and Regional Development: The Cases of Cambridge and Scotland. Eur Plan Stud [Internet]. 2011 Mar [cited 2014 Oct 18];19(3):403–28. Available from: http://www.tandfonline.com/doi/abs/10.1080/09654313.2011.548387

Cooke P. Regional knowledge capabilities, embeddedness of firms and industry organisation: Bioscience megacentres and economic geography. Eur Plan Stud [Internet]. 2004 Jul [cited 2014 Oct 27];12(5):625–41. Available from: http://www.tandfonline.com/doi/abs/10.1080/0965431042000219987

Cockburn IM. The Changing Structure Of The Pharmaceutical Industry. Health Aff [Internet]. 2004 Jan 1 [cited 2014 Nov 4];23(1):10–22. Available from: http://content.healthaffairs.org/cgi/doi/10.1377/hlthaff.23.1.10

Cooke P. The molecular biology revolution and the rise of bioscience megacentres in North America and Europe. Environ Plan C Gov Policy [Internet]. 2004;22(2):161–77. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-2042507101&partnerID=40&md5=8f92da5836ab1e6b044d2dfe10ea8856

Gassmann O, Reepmeyer G. Organizing Pharmaceutical Innovation: From Science-based Knowledge Creators to Drug-oriented Knowledge Brokers. Creat Innov Manag [Internet]. 2005;14(3):233–45. Available from: http://doi.wiley.com/10.1111/j.1467-8691.2005.00344.x

Vallas SP, Kleinman DL. Contradiction, convergence and the knowledge economy: The confluence of academic and commercial biotechnology. Socio-Economic Rev. 2008;6(2):283–311.

Shohet S, Prevezer M. UK biotechnology: institutional linkages, technology transfer and the role of intermediaries. R&D Manag. 1996;26(3):283–98.

Walsh V. Demand, public markets and innovation in biotechnology. Sci Public Policy [Internet]. 1993;20(3):138–56. Available from: http://spp.oxfordjournals.org/content/20/3/138.short

Senker J. National systems of innovation, organizational learning and industrial biotechnology. Technovation. 1996;16(5):219–29.

Cooke P. New Economy Innovation Systems: Biotechnology in Europe and the USA. Ind Innov. 2001;8(3):267–89.

Lynskey MJ. Transformative technology and institutional transformation: Coevolution of biotechnology venture firms and the institutional framework in Japan. Res Policy. 2006;35:1389–422.

Ibata-Arens K. Comparing National Innovation Systems in Japan and the United States: Push, Pull, Drag and Jump Factors in the Development of New Technology. Asia Pacific Bus Rev [Internet]. 2008 Jul [cited 2014 Jul 12];14(3):315–38. Available from: http://www.tandfonline.com/doi/abs/10.1080/13602380802116765

Zhang F, Cooke P, Wu F. State-sponsored Research and Development: A Case Study of China’s Biotechnology. Reg Stud [Internet]. 2011 May [cited 2014 Oct 31];45(5):575–95. Available from: http://www.tandfonline.com/doi/abs/10.1080/00343401003604663

DiMasi J a., Hansen RW, Grabowski HG, Lasagna L. Cost of innovation in the pharmaceutical industry. J Health Econ. 1991;10(2):107–42.

DiMasi J a., Hansen RW, Grabowski HG. The price of innovation: New estimates of drug development costs. J Health Econ. 2003;22(2):151–85.

DiMasi J a. Risks in new drug development: Approval success rates for investigational drugs. Clin Pharmacol Ther. 2001;69(5):297–307.

DiMasi J a, Feldman L, Seckler a, Wilson a. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther [Internet]. 2010;87(3):272–7. Available from: http://dx.doi.org/10.1038/clpt.2009.295

Dohse D. Technology policy and the regions — the case of the BioRegio contest. Res Policy. 2000;29(9):1111–33.

Feldman MP. Where science comes to life: University bioscience, commercial spinâ€offs, and regional economic development. J Comp Policy Anal Res Pract. 2000;2(3):345–61.

Calvert J, Senker J. Biotechnology innovation systems in two small countries: A comparison of Portugal and Ireland. Sci Public Policy [Internet]. 2004;31 (5 ):359–70. Available from: http://spp.oxfordjournals.org/content/31/5/359.abstract

Rosiello A. Examining Scottish Enterprise’s framework for action in life sciences. Int J Biotechnol [Internet]. 2008;10(5):496. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-56549115913&partnerID=tZOtx3y1

Senker J, Enzing C, Reiss T. Biotechnology policies and performance in central and eastern Europe. Int J Biotechnol. 2008;10(4):341–62.

Taggart JH. Determinants of the Foreign Research-and-Development Locational Decision in the Pharmaceutical-Industry. R D Manag [Internet]. 1991;21(3):229–40. Available from: ://WOS:A1991FW08200005

Feldman MP, Ronzio CR. Closing the innovative loop: moving from the laboratory to the shop floor in biotechnology manufacturing. Entrep Reg Dev [Internet]. 2001 Jan;13(1):1–16. Available from: http://www.tandfonline.com/doi/abs/10.1080/08985620010005484

Powell W. Learning From Collaboration: KNOWLEDGE AND NETWORKS IN THE BIOTECHNOLOGY AND PHARMAGEUTIGAL INDUSTRIES. Calif Manage Rev [Internet]. 1998 [cited 2014 Aug 28];40(3):228–41. Available from: http://www.researchgate.net/publication/228038709_Learning_from_Collaboration_Knowledge_and_Networksin_the_Biotechnology_and_Pharmaceutical_Industries/file/3deec51f90f127b781.pdf

Pisano GP. Can science be a business? Lessons from biotech. Harv Bus Rev [Internet]. 2006 Oct;84(10):114–24, 150. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17040044

Krimsky S, Ennis JG, Weissman R. Academic-corporate ties in biotechnology: a quantitative study. Sci Technol Human Values. 1991;16(3):275–87.

Argyres NS, Liebeskind JP. Privatizing the intellectual commons: Universities and the commercialization of biotechnology. J Econ Behav Organ. 1998;35(4):427–54.

Pisano GP. Searching for Viable Biobusiness Models. Genet Eng Biotechnol News. 2007;27(8):1–4.

Whitley R. Developing innovative competences: the role of institutional frameworks. Ind Corp Chang [Internet]. 2002;11(3):497–528. Available from: http://icc.oupjournals.org/cgi/doi/10.1093/icc/11.3.497

Herpin TF, Karuso H, Foley JE. Australian biotech companies: Navigating the maze. J Commer Biotechnol [Internet]. 2005 Jan 1;11(2):111–20. Available from: http://commercialbiotechnology.com/article/view/108

Bierly P, Chakrabarti A. Generic Knowledge Strategies in the U . S . Pharmaceutical Industry. Strateg Manag J. 1996;17(Special Issue: Knowledge and the Firm):123–35.

Khilji S. From Invention to Innovation: Toward developing an integrated innovation model for biotech firms*. J Prod Innov Manag [Internet]. 2006 [cited 2014 Jul 31];23:528–40. Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.1540-5885.2006.00222.x/full

Grabowski H, Vernon J. Innovation and structural change in pharmaceuticals and biotechnology. Ind Corp Chang [Internet]. 1994 [cited 2014 Aug 9];3(2):435–49. Available from: http://icc.oxfordjournals.org/content/3/2/435.short

Oliver AL, Montgomery K. Creating a hybrid organizational form from parental blueprints: The emergence and evolution of knowledge firms. Hum Relations. 2000;53(I):33–56.

Friedman Y. Time for a new business model? J Commer Biotechnol [Internet]. 2010 Jan [cited 2014 Apr 26];16(1):1–2. Available from: http://commercialbiotechnology.com/article/view/311

Pisano GP. The evolution of science-based business: innovating how we innovate. Ind Corp Chang [Internet]. 2010 Mar 31 [cited 2014 Sep 28];19(2):465–82. Available from: http://icc.oxfordjournals.org/cgi/doi/10.1093/icc/dtq013

Bernard S. The New Commercial Myth Model. Pharm Exec. 2013;33(5):46–7.

Breznitz SM, O'Shea RP, Allen TJ. University commercialization strategies in the development of regional bioclusters. J Prod Innov Manag. 2008;25:129–42.

Casper S, Kettler H. National Institutional Frameworks and the Hybridization of Entrepreneurial Business Models: the German and Uk Biotechnology Sectors. Ind Innov [Internet]. 2001;8(1):5–30. Available from: http://www.tandfonline.com/doi/abs/10.1080/13662710120034383

Bagchiâ€Sen S, Scully J. The Canadian environment for innovation and business development in the biotechnology industry: a firmâ€level analysis. Eur Plan Stud [Internet]. 2004 [cited 2014 Nov 15];12(7):961–83. Available from: http://www.tandfonline.com/doi/abs/10.1080/0965431042000267867

Bigliardi B, Nosella A, Verbano C. Business models in Italian biotechnology industry: a quantitative analysis. Technovation [Internet]. 2005 Nov [cited 2014 Feb 9];25(11):1299–306. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0166497204002056

Fisken J, Rutherford J. Business models and investment trends in the biotechnology industry in Europe. J Commer Biotechnol. 2002;8(3):191–9.

Williams A. Is partnering an opportunity for a biotechnology company to grow or does it create risk. J Commer Biotechnol. 1998;5(1):12–20.

Pisano GP. The governance of innovation: Vertical integration and collaborative arrangements in the biotechnology industry. Res Policy. 1991;20(3):237–49.

Nosella A, Petroni G, Verbano C. Characteristics of the Italian biotechnology industry and new business models: the initial results of an empirical study. Technovation [Internet]. 2005 Aug [cited 2014 Feb 22];25(8):841–55. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0166497204000276

DiVito L. Institutional entrepreneurship in constructing alternative paths: A comparison of biotech hybrids. Res Policy [Internet]. Elsevier B.V.; 2012 Jun [cited 2014 Aug 9];41(5):884–96. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0048733312000352

Brink J, Holmén M. Capabilities and Radical Changes of the Business Models of New Bioscience Firms. Creat Innov Manag [Internet]. 2009 Jun [cited 2013 Sep 18];18(2):109–20. Available from: http://doi.wiley.com/10.1111/j.1467-8691.2009.00519.x

Rothman H, Kraft A. Downstream and into deep biology: Evolving business models in “top tier†genomics companies. J Commer Biotechnol [Internet]. 2006 Jan 1;12(2):86–98. Available from: http://commercialbiotechnology.com/article/view/154

Willemstein L, van der Valk T, Meeus MTH. Dynamics in business models: An empirical analysis of medical biotechnology firms in the Netherlands. Technovation [Internet]. 2007 Apr [cited 2014 Jan 21];27(4):221–32. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0166497206000964

Mangematin V, Lemarié S, Boissin J-P, Catherine D, Corolleur F, Coronini R, et al. Development of SMEs and heterogeneity of trajectories: the case of biotechnology in France. Res Policy [Internet]. 2003 Apr;32(4):621–38. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0048733302000458

Chaya D. Survival strategies for start-ups. J Commer Biotechnol [Internet]. 2005 Jan 1;11(2):130–3. Available from: http://commercialbiotechnology.com/article/view/110

Persidis A. Strategies of biotechnology firms towards new, platform technologies. Int J Biotechnol [Internet]. 2001;3(1-2):23–32. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-0034973238&partnerID=40&md5=27e6ae28b2a7999cb90ddebacf7ceaa1

March-Chorda I, Yagüe-Perales RM. New directions for the biopharma industry in Canada: modelling and empirical findings. Manag Decis [Internet]. 2008 [cited 2014 Mar 20];46(6):880–93. Available from: http://www.emeraldinsight.com/10.1108/00251740810882653

Sabatier V, Mangematin V, Rousselle T. From Recipe to Dinner: Business Model Portfolios in the European Biopharmaceutical Industry. Long Range Plann [Internet]. 2010 Apr [cited 2014 Feb 6];43(2-3):431–47. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0024630110000075

Boni A. Project, product or company. J Commer Biotechnol [Internet]. 2012 [cited 2014 Apr 2];18(2):13–9. Available from: http://search.ebscohost.com/login.aspx?direct=true&profile=ehost&scope=site&authtype=crawler&jrnl=14628732&AN=84497030&h=ufgJ4VPONHS1a%2BHaa0mObYjp0zfNOsZuHKWiQKY1k10FfbnP4P0BhmiLvpNu8mO1StoFh9Gtqpn6acuzIe%2FOIQ%3D%3D&crl=c

Champion D. Mastering the value chain: An interview with Mark Levin of Millennium Pharmaceuticals. Harv Bus Rev. 2001;June:108–15.

Basile A, Faraci R. A decision-making perspective on business integration and inter-firms agreements in biotechnology industry. Int J Manag Decis Mak [Internet]. 2013;12(4):335–50. Available from: 10.1504/IJMDM.2013.056837nhttp://search.ebscohost.com/login.aspx?direct=true&db=bth&AN=90493806&site=ehost-live

Luukkonen T. Variability in organisational forms of biotechnology firms. Res Policy. 2005;34(4):555–70.

Ursula Weisenfeld, Olaf Fisscher, Alan Pearson KB. Managing technology as a virtual enterprise. R&D Manag [Internet]. 2001 [cited 2014 Sep 13];31(3):323–34. Available from: http://onlinelibrary.wiley.com/doi/10.1111/1467-9310.00220/abstract

Bower JD, Sulej JC. The Indian Challenge: The Evolution of a Successful New Global Strategy in the Pharmaceutical Industry. Technol Anal Strateg Manag. 2007;19(5):611–24.

Malone K, Hales B, Chan J, Love M, Rayner J. Cloning an industry: Strategy typologies of Shanghai biotechnology companies. J Commer Biotechnol [Internet]. 2008 Nov 27 [cited 2014 Jun 23];14(1):31–42. Available from: http://commercialbiotechnology.com/article/view/226

March-Chordà I, Yagüe-Perales RM, Seoane-Trigo R. Asymmetric behaviour of biotechnology business patterns in Spain. Technol Anal Strateg Manag. 2009;21(October 2013):765–82.

Suurna M. The developments in the business models of biotechnology in the Central and Eastern European countries: The example of Estonia. J Commer Biotechnol [Internet]. 2011 Feb [cited 2014 Apr 21];17(1):84–108. Available from: http://commercialbiotechnology.com/article/view/366

Hopkins MM, Crane P a., Nightingale P, Baden-Fuller C. Buying big into biotech: scale, financing, and the industrial dynamics of UK biotech, 1980-2009. Ind Corp Chang [Internet]. 2013 Jul 19 [cited 2014 Feb 3];22(4):903–52. Available from: http://icc.oxfordjournals.org/cgi/doi/10.1093/icc/dtt022

Garnier J-P. Rebuilding the R&D Engine in Big Pharma. Harv Bus Rev. 2008;(May):68–77.

Weisenfeld U, Reeves JC, Hunck-Meiswinkel A. Technology management and collaboration profile: virtual companies and industrial platforms in the high-tech biotechnology industries. R D Manag [Internet]. 2001 Jan;31(1):91–100. Available from: http://doi.wiley.com/10.1111/1467-9310.00199

Baker A. Biotechnology’s growth–innovation paradox and the new model for success. J Commer Biotechnol [Internet]. 2003 Jun 1;9(4):286–8. Available from: http://commercialbiotechnology.com/article/view/38

Hunter J. Is open innovation the way forward for big pharma? Nat Rev Drug Discov. 2010;9:87–8.

Munos B. Can open-source R&D reinvigorate drug research? Nat Rev Drug Discov. 2006;5:723–9.

Melese T, Lin SM, Chang JL, Cohen NH. Open innovation networks between academia and industry: an imperative for breakthrough therapies. Nat Med. 2009;15(5):502–7.

Valle F, Gambardella A. Biological revolution and strategies for innovation in pharmaceutical companies. R&D Manag [Internet]. 1993;23(4):287–302. Available from: http://doi.wiley.com/10.1111/j.1467-9310.1993.tb00835.x

Caples A, Grace J. AMRAD: Pioneer of Australian biotechnology. J Commer Biotechnol [Internet]. 2001 [cited 2014 Jan 19];7(3):260–4. Available from: http://logos-press.com/journals/index.php/jcb/article/view/390

Horn L. Alternative approaches to IP management: One-stop technology platform licensing. J Commer Biotechnol [Internet]. 2003 Jan 1;9(2):119–27. Available from: http://commercialbiotechnology.com/article/view/17

Booth BL. Beyond the biotech IPO: a brave new world. Nat Biotechnol [Internet]. Nature Publishing Group; 2009;27(8):705–9. Available from: http://dx.doi.org/10.1038/nbt0809-705

Lowe NJ, Gertler MS. Building on Diversity: Institutional Foundations of Hybrid Strategies in Toronto’s Life Sciences Complex. Reg Stud [Internet]. 2009 May [cited 2014 Jun 22];43(4):589–603. Available from: http://www.tandfonline.com/doi/abs/10.1080/00343400701875179

Rao SK. Rethinking commercial strategy – A patient-centered commercial model. J Commer Biotechnol [Internet]. 2010 Jul [cited 2014 Apr 21];16(3):206–23. Available from: http://commercialbiotechnology.com/article/view/338

Lessl M, Bryans JS, Richards D, Asadullah K. Crowd sourcing in drug discovery. Nat Rev Drug Discov [Internet]. Nature Publishing Group; 2011;10(4):241–2. Available from: http://dx.doi.org/10.1038/nrd3412

Chesbrough H, Chen E. Recovering Abandoned Compounds Through Expanded External IP Licensing. Calif Manage Rev [Internet]. 2013 [cited 2014 Apr 7];55(4):83–102. Available from: http://search.ebscohost.com/login.aspx?direct=true&profile=ehost&scope=site&authtype=crawler&jrnl=00081256&AN=89460503&h=LzHqYrRoSzFn6DB8mStHe%2FT6o8%2FMYbe08Y89eiXCGz59izphQHlfKAr4wBEnwfBIw4QPohfgmb4rIUXpxdH%2BFw%3D%3D&crl=c

Woiceshyn J, Hartel D. Strategies and performance of Canadian biotechnology firms: An empirical investigation. Technovation. 1996;16(5):231–43.

Rodgers P, Catton D, Duncan GS. Practical experiences in starting up life science companies in the academic sector. J Commer Biotechnol. 2002;8(4):273–80.

Patzelt H, zu Knyphausen-Aufseß D, Nikol P. Top Management Teams, Business Models, and Performance of Biotechnology Ventures: An Upper Echelon Perspective *. Br J Manag [Internet]. 2008 Sep [cited 2014 Mar 29];19(3):205–21. Available from: http://doi.wiley.com/10.1111/j.1467-8551.2007.00552.x

Dodgson M. Strategic alignment and organizational options in biotechnology firms. Technol Anal Strateg Manag. 1991;3(2):115–26.

Ireland DC, Hine D. Harmonizing science and business agendas for growth in new biotechnology firms: Case comparisons from five countries. Technovation. 2007;27(11):676–92.

Forrest JE, Martin MJC. Strategic alliances between large and small research intensive organizations: experiences in the biotechnology industry. R&D Manag [Internet]. 1992;22(1):041–54. Available from: http://doi.wiley.com/10.1111/j.1467-9310.1992.tb00787.x

Henderson R. The evolution of integrative capability: Innovation in cardiovascular drug discovery. Ind Corp Chang. 1994;3(3):607–30.

Hamilton W, Vila J, Dibner M. Patterns of Strategic Choice in Emerging Firms: Positioning for Innovation in Biotechnolgy. Calif Manage Rev [Internet]. 1990 [cited 2014 Oct 11];32(3):73–86. Available from: http://heinonlinebackup.com/hol-cgi-bin/get_pdf.cgi?handle=hein.journals/canusa32&section=38

Vanderbyl S, Kobelak S. Risk management for the biotechnology industry : A Canadian perspective FACTORS AND RISK OF. J Commer Biotechnol. 2008;14(2):128–40.

Henderson R, Cockburn I. Measuring competence? Exploring firm effects in pharmaceutical research. Strateg Manag J. 1994;15(Special):63–84.

Palacios-Marqués D, Peris-Ortiz M, Merigó JM. The effect of knowledge transfer on firm performance: An empirical study in knowledge-intensive industries. Manag Decis [Internet]. 2013;51(5):973–85. Available from: http://www.emeraldinsight.com/journals.htm?issn=0025-1747&volume=51&issue=5&articleid=17089490&show=html

Costa C, Fontes M, Heitor M V. A methodological approach to the marketing process in the biotechnology-based companies. Ind Mark Manag. 2004;33(5):403–18.

Rajamäki H. Anticipating and managing the challenges of biotechnology marketing. J Commer Biotechnol [Internet]. 2008 May 6 [cited 2014 Jun 9];14(3):225–31. Available from: http://commercialbiotechnology.com/article/view/245

Stremersch S, Dyck W Van. Marketing of the life sciences: A new framework and research agenda for a nascent field. J Mark [Internet]. 2009 [cited 2014 Sep 16];73(July):4–30. Available from: http://journals.ama.org/doi/abs/10.1509/jmkg.73.4.4

Estades J, Ramani S V. Technological competence and the influence of networks: a comparative analysis of new biotechnology firms in france and britain. Technol Anal Strateg Manag [Internet]. 1998 Jan [cited 2014 Nov 2];10(4):483–95. Available from: http://www.tandfonline.com/doi/abs/10.1080/09537329808524329

Deeds DL, Hill CWL. Strategic alliances and the rate of new product development: An empirical study of entrepreneurial biotechnology firms. J Bus Ventur. 1996;11(1):41–55.

Rothaermel FT. INCUMBENT ’ S ADVANTAGE THROUGH EXPLOITING COMPLEMENTARY ASSETS VIA INTERFIRM COOPERATION. Strateg Manag J. 2001;22:687–99.

Deeds DL, Decarolis D, Coombs J. Dynamic Capabilities and New Product Development in High Technology Ventures : an Empirical Analysis of New Biotechnology Firms. J Bus Ventur [Internet]. 1999;15(216):211–29. Available from: http://www.sciencedirect.com/science/article/pii/S0883902698000135

Grupp RW, Gaines-Ross L. Reputation management in the biotechnology industry. J Commer Biotechnol [Internet]. 2002 Sep 1;9(1):17–26. Available from: http://commercialbiotechnology.com/article/view/3

Hall L a., Bagchi-Sen S. A study of R&D, innovation, and business performance in the Canadian biotechnology industry. Technovation. 2002;22(4):231–44.

Nickisch KJ, Greuel JM, Bode-Greuel KM. How can pharmaceutical and biotechnology companies maintain a high profitability? J Commer Biotechnol [Internet]. 2009 Aug 11 [cited 2014 Mar 12];15(4):309–23. Available from: http://commercialbiotechnology.com/article/view/303

Walcott SM. Analyzing an Innovative Environment: San Diego as a Bioscience Beachhead. Econ Dev Q. 2002;16(2):99–114.

Thomke S, Kuemmerle W. Asset accumulation, interdependence and technological change: Evidence from pharmaceutical drug discovery. Strateg Manag J. 2002;23(7):619–35.

Patzelt H, Audretsch DB. The evolution of biotechnology in hostile financing environments. J Organ Chang Manag [Internet]. 2008 [cited 2014 Apr 23];21(6):773–85. Available from: http://www.emeraldinsight.com/10.1108/09534810810915772

Decarolis DM, Deeds DL. The Impact of Stocks and Flows of Organizational Knowledge on Firm Performance: An Empirical Investi... more. Strateg Manag J [Internet]. 1999;20(10):15. Available from: http://www.jstor.org/stable/3094157

Myers S, Baker a. Drug discovery--an operating model for a new era. Nat Biotechnol. 2001;19(8):727–30.

Qian G, Li L. Profitability of small- and medium-sized enterprises in high-tech industries: The case of the biotechnology industry. Strateg Manag J. 2003;24(9):881–7.

Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3(August):711–5.

Cohan P, Unger B. Four sources of Advantage. Bus Strateg Rev. 2006;Spring:9–14.

De Carolis DM. Competencies and Imitability in the Pharmaceutical Industry: An Analysis of Their Relationship with Firm Performance. J Manage. 2003;29(1):27–50.

Nerkar a, Roberts PW. Technological and product-market experience and the success of new product introductions in the pharmaceutical industry. Strateg Manag J [Internet]. 2004;25(89):779–99. Available from: http://doi.wiley.com/10.1002/smj.417

Mehta S, Peters L. OUTSOURCING A CORE COMPETENCY. Res Manag [Internet]. 2007 [cited 2014 Apr 2];50(3):28–34. Available from: http://www.ingentaconnect.com/content/iri/rtm/2007/00000050/00000003/art00005

Catherine DF, Corolleur F, Carrere M, Mangematin V. Turning scientific and technological human capital into economic capital: The experience of biotech start-ups in France. Res Policy. 2004;33(4):631–42.

Nilsson A. Biotechnology firms in Sweden. Small Bus Econ [Internet]. 2001 [cited 2014 Feb 1];(1997):93–103. Available from: http://link.springer.com/article/10.1023/A:1011101818877

Cooke P. Biotechnology clusters in the U . K .: Lessons from localisation in the commerci ... Small Bus Econ. 2001;17(1-2):43–60.

Zaheer A, George V. Reach out or reach within? Performance implications of alliances and location in biotechnology. Manag Decis Econ [Internet]. 2004 [cited 2014 Oct 19];25:437–52. Available from: http://onlinelibrary.wiley.com/doi/10.1002/mde.1200/abstract

Ahn MJ, Meeks M, Davenport S, Bednarek R. Exploring technology agglomeration patterns for multinational pharmaceutical and biotechnology firms. J Commer Biotechnol [Internet]. 2009 Apr 7 [cited 2014 Jul 30];16(1):17–32. Available from: http://commercialbiotechnology.com/article/view/315

Appiah-adu K, Ranchhod A. Market orientation and performance in the biotechnology industry: An exploratory empirical analysis. Technol Anal Strateg Manag. 1998;10(April 2015):197–210.

Niosi J. Alliances are not enough explaining rapid growth in biotechnology firms. Res Policy. 2003;32(5):737–50.

Garnsey E. Developmental Conditions of U.K. Biopharmaceutical Ventures. Innovation. 2003;5(2-3):99–119.

Danzon PM, Nicholson S, Pereira NS. Productivity in pharmaceutical–biotechnology R&D: the role of experience and alliances. J Health Econ [Internet]. 2005;24(2):317–39. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0167629604001249

Amir-Aslani A. The Quest for Competitive Sustainability: From Technology Sourcing to Knowledge Management. J Technol Manag Innov [Internet]. 2009 [cited 2015 Jan 25];4(2):54–68. Available from: http://www.scielo.cl/scielo.php?pid=S0718-27242009000200005&script=sci_arttext

Reiss T. Success factors for biotechnology: lessons from Japan, Germany and Great Britain. Int J Biotechnol. 2001;3(1-2):134–56.

Bagchi-Sen S, Smith HL, Hall L. The US biotechnology industry: industry dynamics and policy. Environ Plan C [Internet]. 2004;22(2):199–216. Available from: http://search.proquest.com/docview/37884855?accountid=10297nhttp://sfx.cranfield.ac.uk/cranfield?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&genre=article&sid=ProQ:ProQ:ibssshell&atitle=The+US+biotechnology+industry:+industry+dynamics+an

Cooke P, Kaufmann D, Levin C, Wilson R. The biosciences knowledge value chain and comparative incubation models. J Technol Transf. 2006;31(1):115–29.

Smith HL, Bagchiâ€Sen S. University–Industry Interactions: the Case of the UK Biotech Industry. Ind Innov [Internet]. 2006;13(4):371–92. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-34347256676&partnerID=tZOtx3y1

Bobulescu R, Soulas C. Biotechnologies and innovating strategies in the pharmaceutical industry. J Pharm Financ Econ Policy [Internet]. 2007;16(2):43–60. Available from: http://search.ebscohost.com/login.aspx?direct=true&db=rzh&AN=2009779826&site=ehost-live

Cockburn IM, Henderson RM. Absorptive Capacity, Coauthoring Behavior, and the Organization of Research in Drug Discovery. J Ind Econ. 1998;XLVI(2):157–82.

McMillan GS, Narin F, Deeds DL. An analysis of the critical role of public science in innovation: the case of biotechnology. Res Policy. 2000;29(1):1–8.

Shan W, Walker G, Kogut B. INTERFIRM COOPERATION AND STARTUP INNOVATION IN THE BIOTECHNOLOGY INDUSTRY. Strateg Manag J. 1994;15(December 1993):387–94.

Lecocq C, Leten B, Kusters J, Looy B Van. Do firms benefit from being present in multiple technology clusters? An assessment of the technological performance of biopharmaceutical firms. Reg Stud [Internet]. 2012 [cited 2014 Jul 21];46(October):1107–19. Available from: http://www.tandfonline.com/doi/abs/10.1080/00343404.2011.552494

Henderson R, Cockburn I. Scale, scope, and spillovers: the determinants of research productivity in drug discovery. Rand J Econ. 1996;27(1):32–59.

Zucker LG, Darby MR. Star scientists and institutional transformation: patterns of invention and innovation in the formation of the biotechnology industry. Proc Natl Acad Sci U S A. 1996;93(23):12709–16.

Subramanian AM, Lim K, Soh P-H. When birds of a feather don’t flock together: Different scientists and the roles they play in biotech R&D alliances. Res Policy [Internet]. Elsevier B.V.; 2013 Apr [cited 2014 Dec 6];42(3):595–612. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0048733312002636

Smith D a, Schmid EF. Managing innovation in the pharmaceutical industry. 2005;12(1):50–8.

Frahm J, Ireland DC, Hine D. Constructing a processual model of communication in new product development from a multiple case study of biotechnology SMEs. J Commer Biotechnol. 2007;13(3):151–61.

Casper S, Matraves C. Institutional frameworks and innovation in the German and UK pharmaceutical industry. Res Policy. 2003;32(10):1865–79.

Gittelman M. Does Geography Matter for Science-Based Firms? Epistemic Communities and the Geography of Research and Patenting in Biotechnology. Organ Sci [Internet]. 2007 Aug [cited 2014 Jul 16];18(4):724–41. Available from: http://pubsonline.informs.org/doi/abs/10.1287/orsc.1070.0249

Moodysson J, Coenen L, Asheim B. Explaining spatial patterns of innovation: Analytical and synthetic modes of knowledge creation in the Medicon Valley life-science cluster. Environ Plan A. 2008;40(5):1040–56.

Nesta L, Saviotti PP. Coherence of the Knowledge Base and the Firm’s Innovative Performance : Evidence From the U.S. Pharmaceutical Industry. J Ind Econ. 2005;53(1):123–43.

Miettinen R, Lehenkari J, Tuunainen J. Learning and Network Collaboration in Product Development: How Things Work for Human Use. Manag Learn [Internet]. 2008 Apr 1 [cited 2014 Aug 30];39(2):203–19. Available from: http://mlq.sagepub.com/cgi/doi/10.1177/1350507607087581

Renko M, Carsrud A, Brännback M. The Effect of a Market Orientation, Entrepreneurial Orientation, and Technological Capability on Innovativeness: A Study of Young Biotechnology Ventures in the United States and in Scandinavia. J Small Bus Manag. 2009;47(3):331–69.

Bernstein B, Singh PJ. An integrated innovation process model based on practices of Australian biotechnology firms. Technovation [Internet]. 2006 May [cited 2014 Jun 1];26(5-6):561–72. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0166497204002202

Fetterhoff T, Voelkel D. Managing open innovation in biotechnology. Res Manag [Internet]. 2006;49(3):14–8. Available from: http://www.ingentaconnect.com/content/iri/rtm/2006/00000049/00000003/art00003

Arora A, Gambardella A, Magazzini L, Pammolli F. A Breath of Fresh Air? Firm Type, Scale, Scope, and Selection Effects in Drug Development. Manage Sci [Internet]. 2009 Oct [cited 2014 Jun 10];55(10):1638–53. Available from: http://pubsonline.informs.org/doi/abs/10.1287/mnsc.1090.1055

Galambos L, Sturchio JL. The Pharmaceutical Industry in the Twentieth Century. Hist Technol. 1996;13.2(1996):83–100.

Chang Y-C. Benefits of co-operation on innovative performance: evidence from integrated circuits and biotechnology firms in the UK and Taiwan. R D Manag [Internet]. 2003 Sep;33(4):425–37. Available from: http://doi.wiley.com/10.1111/1467-9310.00308

Kim KY. Strategic R&D alliance factors that impact innovation success in the biotechnology industry. Int J Technol Manag. 2012;59(1-2):116–38.

Gay B, Dousset B. Innovation and network structural dynamics: Study of the alliance network of a major sector of the biotechnology industry. Res Policy [Internet]. 2005;34(10):1457–75. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0048733305001319

Huang H-C. Technological innovation capability creation potential of open innovation: a cross-level analysis in the biotechnology industry. Technol Anal Strateg Manag. 2011;23(1):49–63.

Quintana-García C, Benavides-Velasco C a. Cooperation, competition, and innovative capability: a panel data of European dedicated biotechnology firms. Technovation [Internet]. 2004 Dec [cited 2014 Jul 19];24(12):927–38. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0166497203000609

Persaud A. Enhancing synergistic innovative capability in multinational corporations: An empirical investigation. J Prod Innov Manag [Internet]. 2005 [cited 2014 Jul 28];22(613):412–29. Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.1540-5885.2005.00138.x/full

Hall L a., Bagchi-Sen S. An analysis of firm-level innovation strategies in the US biotechnology industry. Technovation [Internet]. 2007 Jan [cited 2014 May 31];27(1-2):4–14. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0166497206000757

Luo X, Deng L. Do Birds of a Feather Flock Higher? The Effects of Partner Similarity on Innovation in Strategic Alliances in Knowledge-Intensive Industries. J Manag Stud [Internet]. 2009 Sep [cited 2014 Jul 19];46(6):1005–30. Available from: http://doi.wiley.com/10.1111/j.1467-6486.2009.00842.x

Almeida P, Hohberger J, Parada P. Individual scientific collaborations and firm-level innovation. Ind Corp Chang [Internet]. 2011 Jul 6 [cited 2014 Jul 22];20(6):1571–99. Available from: http://icc.oxfordjournals.org/cgi/doi/10.1093/icc/dtr030

Stephan P, Audretsch D, Hawkins R. The knowledge production function: lessons from biotechnology. Int J Technol Manag [Internet]. 2003;19(1/2):165–78. Available from: http://search.proquest.com/docview/19472239?accountid=14732nhttp://bd9jx6as9l.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ:biotechresearch&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.

Raesfeld A Von, Geurts P, Jansen M. When is a network a nexus for innovation? A study of public nanotechnology R&D projects in the Netherlands. Ind Mark Manag [Internet]. Elsevier Inc.; 2012 Jul [cited 2014 May 17];41(5):752–8. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0019850112001216

Mittra J. Life science innovation and the restructuring of the pharmaceutical industry: Merger, acquisition and strategic alliance behaviour of large firms BT - Evolution of the LIfe Science Industries. Technol Anal Strateg Manag [Internet]. 2007;19(3):279–301. Available from: http://dx.doi.org/10.1080/09537320701281540

Chiaroni D, Chiesa V, Massis A De, Frattini F. The knowledge-bridging role of Technical and Scientific Services in knowledge-intensive industries. Int J Technol Manag [Internet]. 2008;41(3/4):249. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-38549158399&partnerID=tZOtx3y1

Nightingale P. Economies of scale in experimentation: knowledge and technology in pharmaceutical R&D. Ind Corp Chang. 2000;9(2):315–59.

Birch K. Alliance-Driven Governance: Applying a Global Commodity Chains Approach to the U.K. Biotechnology Industry. Econ Geogr [Internet]. 2008;84(1):83–103. Available from: http://www3.interscience.wiley.com/journal/122203970/abstract

Hess AH, Rothaermel FT. WHEN ARE ASSETS COMPLEMENTARY? STAR SCIENTISTS, STRATEGIC ALLIANCES, AND INNOVATION IN THE PHARMACEUTICAL INDUSTRY. Strateg Manag J. 2011;32(September 2008):895–909.

Cardinal LB. Technological Innovation in the Pharmaceutical Industry: The Use of Organizational Control in Managing Research and Development. Organ Sci. 2001;12(1):19–36.

Zeller C. Project Teams as Means of Restructuring Research and Development in the Pharmaceutical Industry. Reg Stud [Internet]. 2002 May [cited 2014 Oct 12];36(3):275–89. Available from: http://www.tandfonline.com/doi/abs/10.1080/00343400220122070

Alegre J, Sengupta K, Lapiedra R. Knowledge management and innovation performance in a high-tech SMEs industry. Int Small Bus J [Internet]. 2011 Oct 12 [cited 2014 Jul 31];31(4):454–70. Available from: http://isb.sagepub.com/cgi/doi/10.1177/0266242611417472

Zhao G, Chen W. Ensuring quality science from R to D: An optimal adoption strategy for in-licensing of pharmaceutical innovation. In: IEEE Transactions on Engineering Management. 2011.

Kneller R. Autarkic drug discovery in Japanese pharmaceutical companies: insights into national differences in industrial innovation. Res Policy [Internet]. 2003;32(10):1805–27. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0048733303000623

Feldman M. The locational dynamics of the U.S. biotech industry: Knowledge externalities and the anchor hypothesis. Res Technol Innov. 2005;201–24.

Zeller C. North Atlantic Innovative Relations of Swiss Pharmaceuticals and the Proximities with Regional Biotech Arenas. Econ Geogr [Internet]. 2009 Feb 16;80(1):83–111. Available from: http://doi.wiley.com/10.1111/j.1944-8287.2004.tb00230.x

Plum O, Hassink R. On the Nature and Geography of Innovation and Interactive Learning: A Case Study of the Biotechnology Industry in the Aachen Technology Region, Germany. Eur Plan Stud [Internet]. 2011 Jul [cited 2014 Oct 3];19(7):1141–63. Available from: http://www.tandfonline.com/doi/abs/10.1080/09654313.2011.573128

Audretsch DB, Stephan PE. Company-Scientist Locational Links: The Case of Biotechnology. Am Econ Rev. 1996;86(3):641–52.

Moodysson J, Jonsson O. Knowledge Collaboration and Proximity: The Spatial Organization of Biotech Innovation Projects. Eur Urban Reg Stud [Internet]. 2007 Apr 1 [cited 2014 Aug 23];14(2):115–31. Available from: http://eur.sagepub.com/cgi/doi/10.1177/0969776407075556

Blumenthal D, Causino N, Campbell E, Louis KS. Relationships between academic institutions and industry in the life sciences--an industry survey. N Engl J Med. 1996;334(6):368–73.

George G, Zahra S a., Wood DR. The effects of business-university alliances on innovative output and financial performance: A study of publicly traded biotechnology companies. J Bus Ventur. 2002;17(6):577–609.

Audretsch D, Feldman M. Small-Firm Strategic Research Partnerships: The Case of Biotechnology. Technol Anal Strateg Manag. 2003;15(2):273–88.

Deeds DL, Hill CWL. An examination of opportunistic action within research alliances. J Bus Ventur [Internet]. 1999;14(2):141–63. Available from: http://www.sciencedirect.com/science/article/pii/S0883902697000694

Filson D, Morales R. Equity Links and Information Acquisition in Biotechnology Alliances Equity Links and Information Acquisition in Biotechnology Alliances. J Econ Behav Organ. 2006;59(1):1–28.

Baraldi E, Strömsten T. Controlling and combining resources in networks — from Uppsala to Stanford, and back again: The case of a biotech innovation. Ind Mark Manag [Internet]. Elsevier Inc.; 2009 Jul [cited 2014 Jul 17];38(5):541–52. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0019850109000583

Lerner J, Merges R. The Control of Technology Alliances : An Empirical Analysis of the Biotechnology Industry. J Ind Econ. 1998;46(2):125–56.

Panico C. On the contractual governance of research collaborations: Allocating control and intellectual property rights in the shadow of potential termination. Res Policy. 2011;40(10):1403–11.

Oliver AL. Strategic alliances and the learning life-cycle of biotechnology ï¬rms. Organ Stud. 2001;22(3):467–89.

Rothaermel FT, Deeds DL. Exploration and exploitation alliances in biotechnology: a system of new product development. Strateg Manag J [Internet]. 2004;25(3):201–21. Available from: http://doi.wiley.com/10.1002/smj.376

Aggarwal V, Hsu D. Modes of cooperative R&D commercialization by start ups. Strateg Manag J. 2009;30:835–64.

Zhang J, Baden-Fuller C. The influence of technological knowledge base and organizational structure on technology collaboration. J Manag Stud. 2010;47(4):679–704.

Diestre L, Rajagopalan N. ARE ALL “SHARKS†DANGEROUS? NEW BIOTECHNOLOGY VENTURES AND PARTNER SELECTION IN R&D ALLIANCES. Strateg Manag J. 2012;33:1115–34.

De Mattos C, Burgess TF, Shaw NE. The impact of R & D-specific factors on the attractiveness of small- and medium-sized enterprises as partners vis-à -vis alliance formation in large emerging economies. R&D Manag. 2013;43(1):1–20.

Lynskey MJ. The dismantling of redundant dichotomies: Biotechnology as an exemplar of university–industry collaboration. J Commer Biotechnol [Internet]. 2006 Jan 1;12(2):127–47. Available from: http://commercialbiotechnology.com/article/view/159

Blakeslee WD. Licensing, partnering, strategic alliances and university relationships. J Commer Biotechnol. 2012;18(2):68–71.

Bianchi M, Cavaliere A, Chiaroni D, Frattini F, Chiesa V. Organisational modes for Open Innovation in the bio-pharmaceutical industry: An exploratory analysis. Technovation [Internet]. Elsevier; 2011 Jan [cited 2014 Jul 11];31(1):22–33. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0166497210000337

Hermann AM, Taks JL, Moors E. Beyond Regional Clusters: On the Importance of Geographical Proximity for R&D Collaborations in a Global Economy—the Case of the Flemish Biotech Sector. Ind Innov. 2012;19(6):499–516.

Boardman PC. Beyond the stars: The impact of affiliation with university biotechnology centers on the industrial involvement of university scientists. Technovation. 2008;28(5):291–7.

Liebeskind JP, Oliver AL, Zucker L, Brewer M. Social Networks, Learning, and Flexibility: Sourcing Scientific Knowledge in New Biotechnology Firms. Organ Sci. 1994;7(4):428–43.

Senker J, Sharp M. Organizational learning in cooperative alliances: some case studies in biotechnology. Technol Anal Strateg Manag [Internet]. 1997;9(1):35–51. Available from: http://dx.doi.org/10.1080/09537329708524268

Suarez-Villa L. Collaboration in biotechnology: how inter-firm relations strengthen research efforts in the USA. Int J Technol Manag [Internet]. 2004;27(5):452–64. Available from: http://search.ebscohost.com/login.aspx?direct=true&db=aph&AN=13914989〈=pt-br&site=ehost-live

Gilsing V, Nooteboom B. Exploration and exploitation in innovation systems: The case of pharmaceutical biotechnology. Res Policy. 2006;35(1):1–23.

Hall L, Bagchi-Sen S. An analysis of R&D, innovation and business performance in the US biotechnology industry. Int J Biotechnol. 2001;3(3-4):267–86.

Pavlou AK. Biotechnology M & A insight: Deals and strategies. J Commer Biotechnol. 2003;10(1):85–91.

Higgins MJ. The allocation of control rights in pharmaceutical alliances. J Corp Financ. 2007;13(1):58–75.

Adegbesan JA, Higgins M. THE INTRA-ALLIANCE DIVISION OF VALUE CREATED THROUGH COLLABORATION. Strateg Manag J. 2010;32:187–211.

Kloyer M. Effective control rights in vertical R&D collaboration. Manag Decis Econ [Internet]. 2011 [cited 2014 Jul 27];468(August):457–68. Available from: http://onlinelibrary.wiley.com/doi/10.1002/mde.1545/full

Robinson DTT, Stuart TEE. Financial Contracting in Biotech Strategic Alliances. J Law Econ. 2007;50(3):559–96.

Reuer J, Zollo M, Singh H. Post-formation dynamics in strategic alliances. Strateg Manag J. 2002;23(2):135–51.

Laroia G, Krishnan S. Managing Drug Discovery Alliances For Success. Res Technolgy Manag. 2005;48(5):42–50.

Pisano GP. Using Equity Participation to Support Exchange: Evidence from the Biotechnology Industry. J Law, Econ Organ [Internet]. 1989;5(1):109–26. Available from: http://ideas.repec.org/a/oup/jleorg/v5y1989i1p109-26.html

Schweizer L. Organizational integration of acquired biotechnology companies into pharmaceutical companies: The need for a hybrid approach. Acad Manag J. 2005;48(6):1051–74.

Powell WW. Inter-Organizational Collaboration in the Biotechnology Industry. J Institutional Theor Econ. 1996;152(1):197–215.

McCutchen Jr. WW, Swamidass PM. Explaining the differences in domestic and cross-boundary strategic alliances in the pharmaceutical/biotech industry,. Int J Technol Manag. 1998;15(3-5):490–506.

McCutchen Jr. WW, Swamidass PM, Teng B-S. R&D Risk-Taking in Strategic Alliances: New Explanations for R&D Alliances in the Biopharmaceutical Industry. Manag Int Rev [Internet]. 2004;44(1):53–67. Available from: http://proquest.umi.com/pqdlink?did=622246681&sid=61&Fmt=2&clientId=44986&RQT=309&VName=PQD

Czerepak E a., Ryser S. Drug approvals and failures: implications for alliances. Nat Rev Drug Discov. 2008;7(3):197–8.

Levitte YM, Bagchi-Sen S. Demographics, Innovative Outputs and Alliance Strategies of Canadian Biotech Firms. Eur Plan Stud [Internet]. 2010 May [cited 2014 Jul 19];18(5):669–90. Available from: http://www.tandfonline.com/doi/abs/10.1080/09654311003593986

Oliver AL. On the duality of competition and collaboration: network-based knowledge relations in the biotechnology industry. Scand J Manag [Internet]. 2004 Mar [cited 2014 Oct 3];20(1-2):151–71. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0956522104000272

Bagchi-Sen S, Hall L, Petryshyn L. A study of university-industry linkages in the biotechnology industry: Perspectives from Canada. Int J Biotechnol [Internet]. 2001;3(3-4):390–410. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-0035712283&partnerID=tZOtx3y1

Motohashi K. The changing autarky pharmaceutical R&D process: causes and consequences of growing R&D collaboration in Japanese firms. Int J Technol Manag. 2007;39(1/2):33.

Stuart TE, Ozdemir SZ, Ding WW. Vertical alliance networks: The case of university-biotechnology-pharmaceutical alliance chains. Res Policy. 2007;36(4):477–98.

Al-Laham A, Souitaris V. Network embeddedness and new-venture internationalization: Analyzing international linkages in the German biotech industry. J Bus Ventur. 2008;23(5):567–86.

Bagchi-Sen S. Firm-specific characteristics of R&D collaborators and non-collaborators in US biotechnology clusters and elsewhere. Int J Technol Glob [Internet]. 2004;1(1):92–118. Available from: http://search.ebscohost.com/login.aspx?direct=true&db=bth&AN=14667588&site=ehost-live&scope=site

Arora A, Gambardella A. Evaluating technological information and utilizing it. J Econ Behav Organ. 1994;24(1):91–114.

Xia T, Roper S. From capability to connectivity-Absorptive capacity and exploratory alliances in biopharmaceutical firms: A US-Europe comparison. Technovation. 2008;28(11):776–85.

Zhang J, Baden-Fuller C, Mangematin V. Technological Knowledge Base , R & D Organization Structure and Alliance Formation : Evidence from the Biopharmaceutical Industry. Res Policy. 2007;36(4):515–28.

Cockburn IM, Henderson RM. Scale and scope in drug development: Unpacking the advantages of size in pharmaceutical research. J Health Econ. 2001;20(6):1033–57.

George G, Zahra S a., Wheatley KK, Khan R. The effects of alliance portfolio characteristics and absorptive capacity on performance A study of biotechnology firms. J High Technol Manag Res. 2001;12(2):205–26.

Fabrizio KR. Absorptive capacity and the search for innovation. Res Policy [Internet]. 2009 Mar [cited 2014 May 24];38(2):255–67. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0048733308002771

Coombs JE, Deeds DL. International alliances as sources of capital. J High Technol Manag Res. 2000;11(2):235–53.

Gopalakrishnan S, Scillitoe JL, Santoro MD. Tapping deep pockets: The role of resources and social capital on financial capital acquisition by biotechnology firms in biotech-pharma alliances. J Manag Stud. 2008;45(8):1354–76.

Powell WW, Koput KW, Bowie JI, Smith-Doerr L. The Spatial Clustering of Science and Capital: Accounting for Biotech Firm-Venture Capital Relationships. Reg Stud. 2002;36(3):291–305.

Belsey M, Pavfou AK. Trends underlying early-stage drug discovery and development collaborations from October 2002 to September 2004. J Commer Biotechnol. 2005;II(4):369–73.

Lee DP, Dibner MD. The rise of venture capital and biotechnology in the US and Europe. Nat Biotechnol. 2005;23(6):672–6.

Champenois C, Engel D, Heneric O. What kind of German biotechnology start-ups do venture capital companies and corporate investors prefer for equity investments? Appl Econ [Internet]. 2006 Mar 20 [cited 2014 May 4];38(5):505–18. Available from: http://www.tandfonline.com/doi/abs/10.1080/00036840500391146

Deeds DL, Decarolis D, Coombs JE. The impact of firm-specific capabilities on the amount of capital raised in an initial public. J Bus Ventur [Internet]. 1997;12(1):31. Available from: http://search.ebscohost.com/login.aspx?direct=true&db=buh&AN=9708242714&site=ehost-live

Sowlay M, Lloyd S. The current M&A environment and its strategic implications for emerging biotherapeutics companies. J Commer Biotechnol [Internet]. 2010 Nov 10 [cited 2014 Nov 19];16(2):109–19. Available from: http://commercialbiotechnology.com/article/view/325

Schiff L, Murray F. Biotechnology financing dilemmas and the role of special purpose entities. Nat Biotechnol. 2004;22(3):271–7.

Burns LR, Housman MG, Robinson C a. Market entry and exit by biotech and device companies funded by venture capital. Health Aff (Millwood) [Internet]. 2009 [cited 2014 Sep 14];28(1):w76–86. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19049998

Festel G. Founding angels as early stage investment model to foster biotechnology start-ups GAP THROUGH BUSINESS GAP THROUGH FOUNDING. J Commer Biotechnol. 2011;17(February):165–71.

Roberts EB, Hauptman O. The Financing Threshold Effect on Success and Failure of Biomedical and Pharmaceutical Start-Ups. Manage Sci. 1987;33(3):381–94.

Kalamas J, Pinkus G. The optimum time for drug licensing. Nat Rev Drug Discov [Internet]. 2003;2(9):691–2. Available from: www.ncbi.nlm.nih.gov/pubmed/12953694

Audretsch DB. The Role of Small Firms in U.S. Biotechnology Clusters. Small Bus Econ. 2001;17(1-2):3–15.

Niosi J, Bas T. The competencies of regions–Canada’s clusters in biotechnology. Small Bus Econ [Internet]. 2001;31–42. Available from: http://www.springerlink.com/index/XR5P148N70837R1T.pdf

Kaufmann D, Schwartz D, Frenkel A, Shefer D. The Role of Location and Regional Networks for Biotechnology Firms in Israel. European Planning Studies. 2003. p. 823–40.

Mytelka L. Clustering, long distance partnerships and the SME: a study of the French biotechnology sector. Int J Technol Manag [Internet]. 2004 [cited 2014 Jul 11];1–22. Available from: http://inderscience.metapress.com/index/xvqcffthp3d1bc7g.pdf

Krauss G, Stahlecker T. New Biotechnology Firms in Germany: Heidelberg and the BioRegion Rhine-Neckar Triangle. Small Bus Econ. 2001;17:143–53.

Gertler M, Levitte Y. Local Nodes in Global Networks: The Geography of Knowledge Flows in Biotechnology Innovation. Ind Innov [Internet]. 2005 [cited 2014 Aug 31];12:487–507. Available from: http://www.tandfonline.com/doi/abs/10.1080/13662710500361981

Waxell A. Guilty by Association: A Cross-industrial Approach to Sourcing Complementary Knowledge in the Uppsala Biotechnology Cluster. Eur Plan Stud. 2009;17(11):1605–24.

Prevezer M. The Dynamics of Industrial Clustering in Biotechnology. Small Bus Econ. 1997;9:255–71.

Stuart TE, Sorensen O. The geography of opportunity:Spatial heterogeneity in founding rates and the perfromance of biotechnology firms. Res Policy. 2003;32:229–53.

Casper S, Karamanos A. Commercializing Science in Europe: The Cambridge Biotechnology Cluster. Eur Plan Stud. 2003;11(7):805–22.

Cooke P. Life sciences clusters and regional science policy. Urban Stud [Internet]. 2004;41(5-6):1113–31. Available from: http://usj.sagepub.com/cgi/doi/10.1080/00420980410001675814

Nelsen LL. The role of research institutions in the formation of the biotech cluster in Massachusetts: The MIT experience. J Commer Biotechnol. 2005;11(4):330–6.

Casper S. How do technology clusters emerge and become sustainable? Res Policy [Internet]. 2007 May [cited 2014 Jul 23];36(4):438–55. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0048733307000510

van Geenhuizen M, Reyes-Gonzalez L. Does a clustered location matter for high-technology companies’ performance? The case of biotechnology in the Netherlands. Technol Forecast Soc Change. 2007;74(9):1681–96.

Lemarié S, Mangematin V, Torre a. Is the Creation and Development of Biotech SMEs Localised? Conclusions Drawn from the French Case. Small Bus Econ. 2001;17(1-2):61–76.

Jommi C, Paruzzulo S. Public administration and R&D localisation by pharmaceutical and biotech companies: A theoretical framework and the Italian case-study. Health Policy (New York). 2007;81(1):117–30.

Cooke P. Rational drug design, the knowledge value chain and bioscience megacentres. Cambridge J Econ. 2005;29(3):325–41.

Murray F. The role of academic inventors in entrepreneurial firms: Sharing the laboratory life. Res Policy. 2004;33(4):643–59.

Salman N, Saives A-L. Indirect networks: an intangible resource for biotechnology innovation. R D Manag [Internet]. 2005 Mar;35(2):203–15. Available from: http://doi.wiley.com/10.1111/j.1467-9310.2005.00383.x

Powell WW, Powell WW, White DR, White DR, Owen-smith J, Owen-smith J, et al. Network Dynamics and Field Evolution: The Growth of Interorganizational Collaboration in the Life Sciences. Am J Sociol. 2005;110(4):1132–205.

Owen-Smith J, Powell WW. Knowledge Networks as Channels and Conduits: The Effects of Spillovers in the Boston Biotechnology Community. Organ Sci [Internet]. 2004 Feb [cited 2014 Jul 9];15(1):5–21. Available from: http://pubsonline.informs.org/doi/abs/10.1287/orsc.1030.0054

Lane C, Probert J. The External Sourcing of Technological Knowledge by US Pharmaceutical Companies: Strategic Goals and Interâ€organizational Relationships. Ind Innov. 2007;14(1):5–25.

Hendry C, Brown J. Organizational Networking in UK Biotechnology Clusters. Br J Manag [Internet]. 2006 Mar [cited 2014 Mar 30];17(1):55–73. Available from: http://doi.wiley.com/10.1111/j.1467-8551.2005.00464.x

Riccaboni M, Pammolli F. Technological regimes and the evolution of networks of innovators. Lessons from biotechnology and pharmaceuticals. Int J Technol Manag. 2003;25(3-4):334–49.

Rank C, Rank O, Wald A. Integrated versus core-periphery structures in regional biotechnology networks. Eur Manag J. 2006;24(1):73–85.

Karamanos AG. Leveraging micro- and macro-structures of embeddedness in alliance networks for exploratory innovation in biotechnology. R&D Manag [Internet]. 2012 Jan 27;42(1):71–89. Available from: http://doi.wiley.com/10.1111/j.1467-9310.2011.00664.x

Powell WW. The Social Construction of an Organisational Field: The Case of Biotechnology. Int J Biotechnol. 1999;1(1):42–66.

Traoré N. Networks and Rapid Technological Change: Novel Evidence from the Canadian Biotech Industry. Ind Innov [Internet]. 2006;13(1):41–68. Available from: http://www.tandfonline.com/doi/abs/10.1080/13662710500513425

Roijakkers N, Hagedoorn J. Inter-firm R&D partnering in pharmaceutical biotechnology since 1975: Trends, patterns, and networks. Res Policy. 2006;35(3):431–46.

Kaufmann D, Schwartz D. Networking strategies of young biotechnology firms in Israel. Ann Reg Sci. 2009;43(3 SPEC. ISS.):599–613.

Tolstoy D, Agndal H. Network resource combinations in the international venturing of small biotech firms. Technovation [Internet]. Elsevier; 2010;30(1):24–36. Available from: http://dx.doi.org/10.1016/j.technovation.2009.06.004

Sabatier V, Mangematin V, Rousselle T. Orchestrating networks in the biopharmaceutical industry: small hub firms can do it. Prod Plan Control. 2010;21(2):218–28.

Mowery D, Nelson R, Sampat B, Ziedonis A. Ivory Tower and Industrial Innovation: University-Industry Technology Transfer Before and After the Bayh-Dole Act. Stanford, CA: Stanfford University Press; 2004. 10 p.

Stokes DE. Pasteur’s Quadrant—Basic Science and Technological Innovation. Washington, DC: Brookings Institution Press; 1997.

Unless specified by prior arrangement, the author agrees to the following terms and assurances:

  1. For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
  2. I/we further give to the following assurances
    1. I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
    2. I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
    3. To the best of my/our knowledge, all the facts in the contribution are true and accurate;
    4. The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
    5. Nothing in the contribution is obscene or libellous;
    6. Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
    7. I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).
* Works by US government employees prepared as part of official duties are in the public domain and the authors are therefore exempt from copyright assignment.